Results: Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated serum transaminases and vomiting. No intratumoural haemorrhages were observed.
Introduction
Central nervous system (CNS) tumours are the second most frequent malignancy and most common form of solid tumour in children. With a 5-year survival rate of 65%, these tumours are the leading cause of cancer-related mortality in children, despite aggressive multi-modal therapy. 1 In addition, effects of either treatment or the tumour itself often leave survivors of childhood CNS tumours with significant neurologic, neurocognitive and psychosocial sequelae. 1, 2 Better treatment approaches are needed. Imatinib mesylate (STI571) is a targeted small molecule competitive inhibitor of subclass III receptor tyrosine kinases, including KIT and PDGFRA. 3, 4 KIT is a proto-oncogene that encodes KIT (CD117), 5 which, when bound to its ligand stem cell factor, is implicated in signalling leading to cell proliferation. 6 The role of KIT in tumourigenesis has been best studied in gastrointestinal stromal tumours (GISTs) where KIT is commonly mutated, causing constitutive, ligand-independent activations of KIT responsible for oncogenic potential. 7, 8 The two PDGF receptors, a and b, can be found on fibroblasts, glial cells and vascular smooth muscle cells, where PDGF binding results in cell proliferation, differentiation and migration. 9 In addition, studies show that imatinib reduces the expression of VEGF, a downstream effector in the PDGF pathway, 10 suggesting that imatinib may have indirect antiangiogenic activity via its inhibition of PDGFRA. Mutations in both the PDGFRA and KIT genes correlate with GIST tumour response to treatment. 4 Imatinib treatment has shown significant clinical responses in KIT-expressing GIST 11, 12 in adults, and in chronic myeloid leukaemia (CML) expressing the BCR-ABL fusion protein in both adults 13 and children. 14, 15 Overexpression of KIT and PDGFRA has been demonstrated in multiple paediatric brain tumours; medulloblastoma, 16 neuroblastoma, 17 intracranial germinoma, 18 and more recently astrocytoma, 19 showed KIT overexpression, while PDGFRA was overexpressed in paediatric astrocytoma and in a small percentage of paediatric gliomas. 19, 20 Evidence of successful clinical studies in malignancies expressing imatinib targets, and of target expression in various paediatric brain tumours, provided the rationale to conduct a phase II study evaluating efficacy and safety of imatinib in paediatric patients with recurrent or refractory CNS tumours. Objectives of the study were: to assess clinical efficacy, safety and pharmacokinetics of imatinib; to assess the frequency of KIT and PDGFRA expression and to correlate efficacy with expression.
2.
Patients and methods
Patients
This was a multi-centre Canadian study. Patients 621 years of age with histologically confirmed recurrent or refractory CNS tumours expressing KIT and/or PDGFRA by immunohistochemistry were eligible for study. Patients were stratified into those with (stratum 1) or without (stratum 2) leptomeningeal dissemination of disease. At baseline, patients were required to have measurable disease documented by CT or MRI. Leptomeningeal dissemination was defined as positive findings on spine MRI, or as presence of malignant cytology or abnormally high protein in cerebrospinal fluid (CSF). Additional eligibility criteria included Lansky performance score P40% or Karnofsky score P50%, life expectancy P8 weeks, adequate bone marrow function (ANC P1500/lL, platelet count P100,000/lL haemoglobin P8.0 g/dL), adequate liver function (total bilirubin 61.5 · upper limit of normal for age, ALT 62.5 · upper limit of normal for age), adequate renal function (age-adjusted normal serum creatinine or GFR P70 ml/ min/1.73 m 2 ) and normal coagulation (INR 61.5, PTTand fibrinogen normal). Negative pregnancy tests were required in postmenarchal females. All patients of reproductive age agreed to effective contraceptive use. Pregnant or breast-feeding women were excluded. Patients requiring drugs known to activate the cytochrome p450 enzyme system (including enzyme-inducing anti-epileptic drugs) and patients with medical conditions that could alter imatinib metabolism were excluded.
The study was approved by the institutional review board of each participating institution and conducted in accordance with the institutional and federal guidelines for human investigations. Patients and parents signed institutional review board-approved informed consent forms before enrolment.
2.2.
Criteria for response and progression 
Treatment administration
Patients had to begin treatment within 14 days of obtaining radiological proof of recurrent or refractory disease. Imatinib was provided by Novartis Pharmaceuticals in 100 mg capsules. Patients in both strata took imatinib orally at a dose of 440 mg/m 2 /day (rounded to nearest multiple of 100 mg) for courses of 28 days with no interruptions. Imatinib was divided BID for doses P600 mg/day, and given to a maximum dose of 800 mg/day. No dose escalation was allowed. Patients with PD or unacceptable toxicity were taken off study. In the absence of PD, drug-related toxicities were managed by dose interruption or reduction based on the protocol guidelines. Patients who demonstrated SD, PR or CR were eligible to receive therapy for up to 2 years. No other cancer chemotherapy or immunomodulating agents were used.
Definition of toxicity
Toxicities were graded using National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0. Safety assessments included regular monitoring of haematological parameters, blood chemistry analysis, urinalysis, vital signs, physical condition and weight. For adverse events and serious adverse events, severity, duration, outcome and presumed relationship to study drug were recorded.
Pharmacokinetic evaluation
On day one of treatment, 2 ml of heparinised blood samples were obtained before morning drug administration and at hours 0.5, 1, 2, 3, 4, 8, 11:55 (before second dose if BID dosing), 24 and 48 following drug administration. A trough level on day 8 was obtained prior to drug ingestion. Plasma was prepared by centrifugation and stored at -80°C until it was analysed for drug content. Sampling of CSF was done at baseline in cases of leptomeningeal dissemination, and repeated 4 h after morning drug administration on day 15, 28 (end of cycle 1) and 56 (end of cycle 2). Plasma and CSF concentrations of imatinib and its active metabolite N-desmethyl-imatinib (CGP74588) were determined using a validated liquid chromatography/mass spectrometry assay as previously reported. 21 
QRT-PCR evaluation for KIT and PDGFRA
For quantitative real-time PCR (QRT-PCR), 10 lm sections of paraffin blocks were cut and selected areas containing at least 85% of tumour were marked for DNA isolation as previously described. 22 QRT-PCR was performed with LightCycler (Roche Molecular Biochemicals, Mannheim, Germany). Primers and probes were designed to amplify a 124 bp (exon 18 from PDG-FRA gene), 163 bp (exon 17 from KIT gene) and 147 bp (18S gene) specific PCR product, where 18S was used as reference gene. PCR amplification conditions, primers and probes for 18S and KIT were previously described. 22 For PDGFRA, conditions were as follows:
Evaluation of data was performed using the DDCt method: DDCt = DCt Tumour DNA -DCt Normal blood DNA. DCt (threshold cycles) is the Ct of the reference gene minus the Ct of the target gene. Fold increase of the target gene was calculated by 2(DDCt).Values between 2 and 5 were considered as aneuploidy and values P5 were considered as gene amplification.
Statistical analysis
The study was designed as an intent-to-treat study. The primary end-point was objective response rate as assessed by RECIST criteria. Secondary end-point criteria included toxicities as assessed by the NCI-CTC, and pharmacokinetic data, including maximum concentration, steady-state concentration and half-life.
Results

Study cohort
Between August 25, 2003 and March 26, 2007, 19 patients were enroled for the study at 5 study centres: 9 patients without, and 10 patients with, CNS dissemination (strata 1 and 2, respectively). Median age at study entry was 10 (range 3-18) for stratum 1 and 8.5 (range 2-17) for stratum 2. Characteristics of patients are presented in Table 1 . One patient was excluded from analysis of toxicity due to very early progression. Seven patients consented to blood draws for pharmacokinetics but only five were fully evaluable. No patients had 48-hour samples taken on day 1 due to issues of consent. One patient consented to CSF samples for pharmacokinetics analysis. Archival frozen tumour samples for retrospective QRT-PCR analysis of gene amplification were available for three patients.
Safety and toxicity
Safety was assessed in 18 patients who completed P1 course of imatinib. At the time of study closure, 70 total courses of imatinib had been administered: 57 in stratum 1, and 13 in stratum 2. Median number of cycles per patient was one for stratum 1 (range 1-26), and one for stratum 2 (range 1-4). Most patients received imatinib daily with no interruptions. However, two patients had P7 days of treatment interruption due to toxicities likely related to imatinib: one patient had grade 3 diarrhoea in courses 2 and 4, with treatment interruption for 7 and 8 days, respectively; another patient had hypoalbuminaemia and oedema in cycle 7, with treatment interruption for 20 consecutive days. Both the patients were in stratum 1. Dose reductions following adverse events were made in two stratum 1 patients after course 1. Of all study patients, five (four in stratum 1) received imatinib for P16 weeks, and four (all stratum 1) received for P38 weeks. Course 1 adverse events are summarised in Table 2 . Haematological toxicities were common during course 1; lymphopaenia, neutropaenia, thrombocytopaenia and leucopaenia all occurred in P4 (20%) of patients. The most commonly reported non-haematological toxicities in course 1 were vomiting, nausea, diarrhoea, elevated ALT, skin rash and fatigue.
Three serious adverse events were considered related to imatinib. One patient was hospitalised during course 1 for disseminated shingles infection with high-grade thrombocytopaenia and ALT/AST elevation; this patient died while on Prior BMT Number of patients 0 1 1 GBM, glioblastoma multiforme; PNET, primitive neuroectodermal tumour; SD, stable disease; PD, progressive disease; RT, radiation therapy; BMT, bone marrow transplant. a Lansky (patients <10-years-old) or Karnofsky (patients P10-years-old) score was used. N = 17, as scores were not available for two stratum 1 patients.
b N = 16; two patients in stratum 1 and one patient in stratum 2 had refractory tumours, and thus had no relapses. study due to PD. Another patient experienced severe hypoalbuminaemia and oedema, vomiting, diarrhoea and constipation post-course 7. After recovery, treatment was resumed at 75% dose. Another patient was hospitalised during course 9 for pneumonia, thrombocytopaenia, diarrhoea, ascites and haemorrhagic pleural and pericardial effusions, and was taken off study due to unacceptable toxicity. Five patients died within 28 days of the last dose of imatinib. None were related to the study drug.
Outcome results
Tumour response was assessed in all 19 patients. There were no PRs or CRs to treatment. Four patients maintained SD P38 weeks on treatment (all stratum 1), including one patient each with ependymoma, astrocytoma, medulloblastoma and primitive neuroectodermal tumour (PNET). All others had progressed by 16 weeks. The PNET patient had SD with a refractory tumour upon study entry, maintained SD for 104 weeks (26 courses), and was taken off study after completion of 2 years. This patient progressed 6 months later. Of the patients who maintained SD, three of four were progressing prior to study entry. The PNET patient entered the study with refractory SD, maintained SD for 104 weeks (26 courses) with imatinib treatment, and was taken off study after completion of 2 years. This patient progressed 6 months later. The astrocytoma, medulloblastoma, and ependymoma patients all had PD upon study entry and maintained SD for 38, 38, and 39 weeks, respectively, with imatinib treatment. The medulloblastoma patient still had SD when taken off study for unacceptable toxicity (pericardial and pleural effusion) at 38 weeks. The others were taken off study for PD.
Pharmacokinetic analyses
Pharmacokinetic data were available for five patients. Based on body surface area, one patient received 500 mg/day, three received 600 mg/day (300 mg BID), and one received 700 mg/ day (300 and 400 mg). Patients receiving doses of BID underwent PK analysis based on the 300 mg morning dose. CSF samples were available for one patient at the 300 mg BID dose level. Considerable interpatient variability of imatinib pharmacokinetics was observed. Details are reported in Table 3 . The CSF samples were obtained at pre-treatment, day 15 and day 28. At day 28 the sample was contaminated with blood and was not useable. At day 15, imatinib concentration was 92 ng/ml and CGP74588 concentration was 13 ng/ml. This was less than 5% of corresponding plasma levels, suggesting a weak penetration of imatinib into the CNS.
3.5.
Immunostaining results
While assessing study eligibility, 35 total patient tumour samples were tested for KIT and PDGFRA immunostaining. All 35 patients were immunopositive for PDGFRA, while only 17 (49%) were immunopositive for KIT. No single tumour type showed a reliable pattern of KIT expression. Only 5 of 8 (63%) medulloblastoma/PNET patients tested positive for a Note that one patient was excluded from evaluation of toxicity, because this patient did not complete a full course of imatinib. b Imatinib had to be held for 8 days for one of these patients.
KIT, which is inconsistent with our previous findings that 10 of 10 medulloblastoma samples expressed KIT. 16 Of the 19 study patients, 11 (58%) were positive for KIT. Of note, however, is that of the 4 patients with SD at 38 weeks, all 4 (100%) were KIT positive.
QRT-PCR evaluation for KIT and PDGFRA
Archival pre-treatment tumour pathology specimens were available for three of 19 study patients. The samples were evaluated retrospectively for amplification of KIT and PDGFRA genes to assess for correlation with response to imatinib. None of the tumours samples exhibited gene amplification of either KIT or PDGFRA, thus we were unable to assess relation to outcome.
Discussion
Imatinib at a dose of 440 mg/m 2 /day was evaluated in the treatment of recurrent or refractory paediatric CNS tumours expressing KIT or PDGRFA. Given the efficacy of imatinib treatment in cancers expressing these targets and confirmation of expression in patients' tumour samples, there was strong rationale to evaluate imatinib in this setting.
No objective tumour responses (either CR or PR) were observed. Another recent paediatric study of imatinib treatment for CNS tumours shows similarly disappointing results, with no CRs observed, and very low PR rates. 23 A recent study in adult recurrent gliomas showed similarly poor clinical responses. 24 In this study, four patients (21%) maintained SD longer than 38 weeks, yet all but one had progressed by 1 year. This is congruent with the above-mentioned study in adult recurrent gliomas, in which imatinib treatment resulted in SD in 25%, and in PR in only 5% of patients. 24 Another recent study on recurrent adult gliomas showed SD in 20%, and PR in 4% of patients. 25 These data suggest that imatinib may have cytostatic activity in adult CNS tumours. Given that some patients with PD just prior to study entry achieved SD with imatinib treatment, our data suggest some cytostatic activity of imatinib in paediatric CNS tumours. Given that all four patients with SD at 38 weeks had KIT-expressing tumours, KIT may correlate with maintenance of SD with imatinib treatment. However, we cannot draw firm conclusions about cytostatic activity of imatinib or the correlation of KIT with SD, because the heterogeneity and rarity of these tumours limit the availability of historical controls for comparison. There are several potential explanations for lack of objective response to imatinib treatment. Imatinib penetration of the blood brain barrier (BBB) is poor. Recent reports have documented CSF imatinib levels 40-to 92-fold lower than the corresponding plasma levels in adults with intact BBBs treated for CML and acute lymphoblastic leukaemia. 26, 27 Data from our study showed that CSF levels of imatinib are less than 5% of the corresponding plasma levels. Access to the CSF is likely limited by drug efflux pumps such as P-glycoprotein, which is highly expressed in the BBB. 28 Low CSF concentrations of imatinib likely contribute to its limited efficacy in CNS tumours, despite the possibility for partial BBB disruption in these patients. Dasatinib, a second-generation receptor tyrosine kinase inhibitor crosses the BBB effectively despite P-glycoprotein expression, and has shown a significant clinical activity in adult CML patients with CNS involvement. 29 Future assessment of the efficacy of secondgeneration tyrosine kinase inhibitors in CNS tumours should be considered. Previous studies assessing imatinib in CNS tumours, which have based treatment rationale on published findings that these tumour types frequently overexpress imatinib targets, have found similarly limited evidence of clinical efficacy of imatinib as a single agent. To our knowledge, this study is the first to use target receptor expression status as eligibility criteria for an imatinib study. Despite the fact that the patient tumours had confirmed the expression of imatinib targets, treatment showed limited clinical activity in paediatric CNS tumours. This suggests that target expression is not sufficient to predict imatinib activity. However, the mutation status of both KIT and PDGFRA has been found retrospectively to be predictive of imatinib response in GIST. 4, 30 In addition, the specific mutation genotype of KIT is predictive of the imatinib dose required for clinical responses in GIST; tumours with exon 11 mutations responded to low dose imatinib, while a Patients at 300 mg dose for pharmacokinetics were those with doses of 600 or 700 mg/day divided BID. Their trough level was taken at 11:55 h, prior to their second dose. The patient at 500 mg dose level had a daily imatinib dose of 500 mg/day taken at once. This patient's trough level was taken at 23:55 h, prior to dosing for the next day.
tumours with exon 9 mutations or wild-type KIT benefited from treatment with higher doses of imatinib. 31 Given these findings, future studies of imatinib combinations in paediatric CNS tumours should consider mutational analysis, rather than expression, of KIT and PDGFRA as potential predictors of tumour response to imatinib. This study confirmed the phase II dose of 440 mg/m 2 /day for imatinib treatment in children.
14 Toxicities were acceptable and all had been previously reported in children. 14, 23 None of the patients experienced intratumoural haemorrhage, a previously reported toxicity associated with imatinib treatment for solid tumours in children and adults. 23, 25 Pharmacokinetic analysis showed a considerable interpatient variability, as seen in previously published paediatric studies using a similar dosing. 14, 23 Compared with these studies, our data show similar ranges for serum C max on day 1 and day 8 for both imatinib and its active metabolite CGP74588. The findings of SD in this study and prior adult studies suggest cytostatic activity of imatinib in some CNS tumours. 24, 25 In a recent phase I study of recurrent malignant gliomas in adults, combination of imatinib with temozolomide was well tolerated and showed promising results, with 12% of patients achieving PR or CR. 32 Imatinib in combination with a cytotoxic agent may have a similar clinical efficacy in paediatric CNS tumours. Future preclinical and phase I studies are needed to evaluate the safety and preliminary evidence of efficacy of this treatment.
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